Pik-Pharma applied for a scarce epilepsy drug

Pik-Pharma applied for a drug for epilepsy, the lack of which funds complained about

Pik-Pharma filed documents for registration of a generic drug based on ethosuximide in December. Last year, charities reported shortages of anticonvulsants to treat epileptic seizures in children.

Pik-Pharma has begun the registration procedure in Russia for its generic Epileksid based on ethosuximide for epilepsy. About it in the company told “Kommersant”.

According to Pik-Pharma, a dossier for consideration under the EAEU regulations for a drug in the form of a syrup, which will be produced from a substance imported from the Netherlands, was submitted at the end of December 2021. The company plans to start deliveries in mid-2023.

Ethosuximide in the form of a syrup, unlike the drug in capsules, is not included in the list of essential drugs (VED), and its wholesale and retail mark-ups are not regulated by the Ministry of Health. This will allow the company to produce the drug “without compromising profitability,” Sergey Shulyak, CEO of DSM Group, told the publication.

The analytical company DSM Group calculated that from January to November last year, sales of this drug did not exceed 12 million rubles, or 24 thousand packs.